Department of Infectious Diseases, Viro-immunology Research Unit, Rigshospitalet, Copenhagen, Denmark.
Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK.
HIV Med. 2019 Nov;20(10):639-647. doi: 10.1111/hiv.12778. Epub 2019 Jul 29.
While renal impairment is reported more frequently in people living with HIV (PLWH) than in the general population, the PLWH samples in previous studies have generally been dominated by those at high renal risk.
Caucasian PLWH who were virologically suppressed on antiretroviral treatment and did not have injecting drug use or hepatitis C were recruited from the Copenhagen Comorbidity in HIV Infection (COCOMO) study. Sex- and age-matched controls were recruited 1:4 from the Copenhagen General Population Study up to November 2016. We defined renal impairment as one measurement of estimated glomerular filtration rate ≤ 60 mL/min/1.73 m , and assessed associated factors using adjusted logistic regression models. The impact of HIV-related factors was explored in a subanalysis.
Among 598 PLWH and 2598 controls, the prevalence of renal impairment was 3.7% [95% confidence interval (CI) 2.3-5.5%] and 1.7% (95% CI 1.2-2.2%; P = 0.0014), respectively. After adjustment, HIV status was independently associated with renal impairment [odds ratio (OR) 3.4; 95% CI 1.8-6.3]. In addition, older age [OR 5.4 (95% CI 3.9-7.5) per 10 years], female sex [OR 5.0 (95% CI 2.6-9.8)] and diabetes [OR 2.9 (95% CI 1.3-6.7)] were strongly associated with renal impairment. The association between HIV status and renal impairment became stronger with older age (P = 0.02 for interaction). Current and nadir CD4 counts, duration of HIV infection and previous AIDS-defining diagnosis were not associated with renal impairment among virologically suppressed PLWH.
The prevalence of renal impairment is low among low-risk virologically suppressed Caucasian PLWH, but remains significantly higher than in controls. Renal impairment therefore remains a concern in all PLWH and requires ongoing attention.
与一般人群相比,HIV 感染者(PLWH)中肾功能损害更为常见,但之前的研究中的 PLWH 样本通常以高肾风险人群为主。
从哥本哈根感染 HIV 合并症(COCOMO)研究中招募了接受抗病毒治疗且病毒学抑制、无注射吸毒和丙型肝炎的白种人 PLWH。截至 2016 年 11 月,按照性别和年龄 1:4 的比例从哥本哈根普通人群研究中招募了对照组。我们将肾小球滤过率估计值≤60mL/min/1.73m 的一次测量定义为肾功能损害,并使用调整后的逻辑回归模型评估相关因素。在亚分析中探讨了与 HIV 相关因素的影响。
在 598 名 PLWH 和 2598 名对照组中,肾功能损害的患病率分别为 3.7%(95%CI 2.3-5.5%)和 1.7%(95%CI 1.2-2.2%;P=0.0014)。调整后,HIV 状态与肾功能损害独立相关[比值比(OR)3.4;95%CI 1.8-6.3]。此外,年龄较大[每增加 10 岁,OR 5.4(95%CI 3.9-7.5)]、女性[OR 5.0(95%CI 2.6-9.8)]和糖尿病[OR 2.9(95%CI 1.3-6.7)]与肾功能损害密切相关。随着年龄的增长,HIV 状态与肾功能损害之间的相关性增强(P=0.02 交互作用)。在病毒学抑制的 PLWH 中,当前和最低 CD4 计数、HIV 感染持续时间和既往 AIDS 定义诊断与肾功能损害无关。
在低危病毒学抑制的白种人 PLWH 中,肾功能损害的患病率较低,但仍明显高于对照组。因此,肾功能损害仍然是所有 PLWH 的关注点,需要持续关注。